Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Fiche publication
Date publication
janvier 2022
Journal
BMC surgery
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric, Dr KAMINSKY Marie-Christine
Tous les auteurs :
Gomes David M, Bakrin N, Salleron J, Kaminsky MC, Bereder JM, Tuech JJ, Lehmann K, Mehta S, Glehen O, Marchal F
Lien Pubmed
Résumé
To investigate the benefit of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of endometrial peritoneal carcinomatosis compared to CRS alone.
Mots clés
Carcinomatosis, Cytoreductive surgery, Endometrial cancer, HIPEC, Peritoneal metastasis
Référence
BMC Surg. 2022 Jan 7;22(1):1